Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811939 · ClinicalTrials.gov registry record · Phase 1
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02811939 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 13 participants.
The verdict
NCT02811939, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The overall purpose of this study is to examine the effect of Pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-Tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with PREG, and then assessing their responses to Dronabinol (THC).
Interventions
- DRUG Active Dronabinol
- DRUG Active Pregnenolone
- DRUG Placebo Dronabinol
- DRUG Placebo Pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2017-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02811939
The ClinicalTrials.gov registry entry for NCT02811939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Active Dronabinol is the first listed.
NCT02811939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02811939 about?
NCT02811939 is a clinical study titled "Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I". The overall purpose of this study is to examine the effect of Pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-Tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with PREG, and then assessing their responses to Dronabinol (THC).
What is the current status of trial NCT02811939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2016-04-07. Estimated completion is 2017-06-09.
What interventions are being tested in trial NCT02811939?
The interventions under investigation include: Active Dronabinol (DRUG), Active Pregnenolone (DRUG), Placebo Dronabinol (DRUG), Placebo Pregnenolone (DRUG).
Who is sponsoring clinical trial NCT02811939?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.